.svg)
our approach
A Scalable Engine for Precision Medicine Innovation
Integrating data science, genetic stratification, patient cohorts, and drug development into one repeatable system that identifies the right patients for the right trials to accelerate precision medicine.
The Precision Medicine Gap in Common Diseases
Precision medicine revolutionized oncology and rare diseases over a decade ago. Yet treatments for common diseases - heart disease, diabetes, and autoimmune conditions - are less tailored to each patient’s biology. For decades, therapies for common diseases have been built for the average patient rather than the individual, prioritizing breadth of indication over depth of benefit.
The challenge is multifaceted: common diseases conditions affect large, diverse populations that have been historically difficult to partition into treatable subgroups. Without effective stratification, targeted therapies don't get developed. Meanwhile, healthcare systems need specialized support to implement genetic testing and deliver personalized care at population scale. The entire ecosystem - from drug development to clinical delivery - requires a new, fully integrated solution.
The Arboretum Approach
Precision Medicine, Fully Integrated
Arboretum transforms the entire ecosystem. By integrating patient stratification, clinical implementation, and drug development, we're making precision medicine work for everyone.
Advanced Genomic Data Science to Stratify Patients
Arboretum brings world-leading expertise to identify biomarkers that predict therapeutic response at the individual level. We identify not just who is at risk, but whose biology makes them most likely to respond to specific treatments. This capability enables both better patient care today, and smarter drug development for tomorrow.
Enabling Genetic Testing at Population Scale
Arboretum partners with healthcare systems to provide clinically-indicated genetic testing, as well as a research registry to provide additional test results to providers and patients at no cost. This model benefits everyone: patients receive life-saving interventions earlier, healthcare systems better adjust for patient risk and further advance standards of care, and together we build the research network essential for precision medicine trials.
Developing Precision Therapies for Common Diseases
Arboretum partners with biopharma to develop precision medicines for common diseases. By redesigning clinical development around biology rather than population averages, we focus on smaller, faster, more informative trials with patients enriched for treatment response. This provides a viable path to develop therapies that affect millions, while reducing both capital requirements and time to market for each therapy.
Contact Us
Partnership inquiries:
partnerships@arboretum.bioGeneral inquiries:
contact@arboretum.bio